1-7 of 7
Ashley E. Ross
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer

Aleksandar Z. Obradovic, Matthew C. Dallos, Marianna L. Zahurak, Alan W. Partin, Edward M. Schaeffer, Ashley E. Ross, Mohamad E. Allaf, Thomas R. Nirschl, David Liu, Carolyn G. Chapman, Tanya O'Neal, Haiyi Cao, Jennifer N. Durham, Gunes Guner, Javier A. Baena-Del Valle, Onur Ertunc, Angelo M. De Marzo, Emmanuel S. Antonarakis, Charles G. Drake
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3182–3192.
https://doi.org/10.1158/1078-0432.CCR-19-3372
Published: 01 July 2020
View article titled, T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
Open the PDF for T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer

Daniel E. Spratt, Mohammed Alshalalfa, Nick Fishbane, Adam B. Weiner, Rohit Mehra, Brandon A. Mahal, Jonathan Lehrer, Yang Liu, Shuang G. Zhao, Corey Speers, Todd M. Morgan, Adam P. Dicker, Stephen J. Freedland, R. Jeffery Karnes, Sheila Weinmann, Elai Davicioni, Ashley E. Ross, Robert B. Den, Paul L. Nguyen, Felix Y. Feng, Tamara L. Lotan, Arul M. Chinnaiyan, Edward M. Schaeffer
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6721–6730.
https://doi.org/10.1158/1078-0432.CCR-19-1587
Published: 15 November 2019
View article titled, Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <em>de novo</em> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Open the PDF for Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <em>de novo</em> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup

David P. Labbé, Christopher J. Sweeney, Myles Brown, Phillip Galbo, Spencer Rosario, Kristine M. Wadosky, Sheng-Yu Ku, Martin Sjöström, Mohammed Alshalalfa, Nicholas Erho, Elai Davicioni, R. Jeffrey Karnes, Edward M. Schaeffer, Robert B. Jenkins, Robert B. Den, Ashley E. Ross, Michaela Bowden, Ying Huang, Kathryn P. Gray, Felix Y. Feng, Daniel E. Spratt, David W. Goodrich, Kevin H. Eng, Leigh Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 7072–7083.
https://doi.org/10.1158/1078-0432.CCR-17-0413
Published: 14 November 2017
View article titled, TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup
Open the PDF for TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup in another window
Includes: Supplementary data
Journal Articles

Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer

Liana B. Guedes, Fawaz Almutairi, Michael C. Haffner, Gaurav Rajoria, Zach Liu, Szczepan Klimek, Roberto Zoino, Kasra Yousefi, Rajni Sharma, Angelo M. De Marzo, George J. Netto, William B. Isaacs, Ashley E. Ross, Edward M. Schaeffer, Tamara L. Lotan
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (16): 4693–4703.
https://doi.org/10.1158/1078-0432.CCR-17-0257
Published: 14 August 2017
View article titled, Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <em>TP53</em> Missense Mutation in Prostate Cancer
Open the PDF for Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <em>TP53</em> Missense Mutation in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157

Noah M. Hahn, Trinity J. Bivalacqua, Ashley E. Ross, George J. Netto, Alex Baras, Jong Chul Park, Carolyn Chapman, Timothy A. Masterson, Michael O. Koch, Richard Bihrle, Richard S. Foster, Thomas A. Gardner, Liang Cheng, David R. Jones, Kyle McElyea, George E. Sandusky, Timothy Breen, Ziyue Liu, Costantine Albany, Marietta L. Moore, Rhoda L. Loman, Angela Reed, Scott A. Turner, Francine B. De Abreu, Torrey Gallagher, Gregory J. Tsongalis, Elizabeth R. Plimack, Richard E. Greenberg, Daniel M. Geynisman
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 3003–3011.
https://doi.org/10.1158/1078-0432.CCR-16-2267
Published: 14 June 2017
View article titled, A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <em>FGFR3</em> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Open the PDF for A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <em>FGFR3</em> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157 in another window
Includes: Supplementary data
Journal Articles

The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer

Shuang G. Zhao, Joseph R. Evans, Vishal Kothari, Grace Sun, Ashley Larm, Victor Mondine, Edward M. Schaeffer, Ashley E. Ross, Eric A. Klein, Robert B. Den, Adam P. Dicker, R. Jeffrey Karnes, Nicholas Erho, Paul L. Nguyen, Elai Davicioni, Felix Y. Feng
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1777–1786.
https://doi.org/10.1158/1078-0432.CCR-15-1250
Published: 31 March 2016
View article titled, The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer
Open the PDF for The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer

Paula J. Hurley, Debasish Sundi, Brian Shinder, Brian W. Simons, Robert M. Hughes, Rebecca M. Miller, Benjamin Benzon, Sheila F. Faraj, George J. Netto, Ismael A. Vergara, Nicholas Erho, Elai Davicioni, R. Jeffrey Karnes, Guifang Yan, Charles Ewing, Sarah D. Isaacs, David M. Berman, Jennifer R. Rider, Kristina M. Jordahl, Lorelei A. Mucci, Jessie Huang, Steven S. An, Ben H. Park, William B. Isaacs, Luigi Marchionni, Ashley E. Ross, Edward M. Schaeffer
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 448–458.
https://doi.org/10.1158/1078-0432.CCR-15-0256
Published: 14 January 2016
View article titled, Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer
Open the PDF for Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer in another window
Includes: Supplementary data